Xeris Biopharma Holdings Market Sentiment

Xeris Biopharma Holdings Inc

XERSNASDAQ

Trade with Public

$10.17

-0.54-5.04%

마지막 업데이트: Nov 3, 7:34 AM

개요 뉴스 실적 전망 이벤트 목표가 재무심리지분 현황 비교 옵션 주식 보고서

실적: Q3 2026 실적이 내일 목 11월 5th에 개장 전 발표됩니다.

컨퍼런스 콜: 내일 8:30 오전에 컨퍼런스 콜이 예정되어 있습니다.

웹캐스트를 보려면 클릭하세요.

Xeris Biopharma Holdings Market Sentiment

Market sentiment signals for Xeris Biopharma Holdings (XERS): analyst consensus, short interest, options flow and insider activity.

Key Signals

Analyst Consensus▲ Buy

Short Interest▼ 4.5% short float

Options Flow— N/A

Insider Activity— N/A

Analyst Consensus

Buy

8 analysts

Options Flow (P/C)

—

Avg Consensus PT

$11

+13.1%

Highest Price Target

$18

+78.9%

Oppenheimer

Lowest Price Target

-40.4%

Jefferies

Short Interest

4.5%

Rising — Bearish

Insider Activity (30d)

—

Short Interest — % of Float

Recent Analyst Actions

Date	Firm	Analyst & Accuracy	Upside / Downside	PT Change	Action	Rating
Oct 6, 2026	Barclays	Glen Santangelo—	+39.2%	$12 → $14	Maintained	Overweight
Sep 10, 2026	Leerink Partners	Roanna Ruiz—	+59.0%	$12 → $16	Maintained	Outperform
Aug 20, 2026	Barclays	Glen Santangelo—	+19.3%	$9 → $12	Maintained	Overweight
Mar 2, 2026	HC Wainwright & Co.	Brandon Folkes—	-0.6%	$10 → $10	Maintained	Buy
Jan 9, 2026	HC Wainwright & Co.	Brandon Folkes—	-0.6%	$10 → $10	Maintained	Buy
Dec 9, 2025	Barclays	Glen Santangelo—	-10.5%	$9	Initiate	Overweight
Nov 7, 2025	Oppenheimer	Leland Gershell—	+78.9%	$18 → $18	Maintained	Outperform
Nov 7, 2025	HC Wainwright & Co.	Brandon Folkes—	-0.6%	$10 → $10	Maintained	Buy
Nov 7, 2025	Piper Sandler	David Amsellem—	-20.5%	$6 → $8	Maintained	Neutral
Oct 29, 2025	Oppenheimer	Leland Gershell—	+78.9%	$8 → $18	Maintained	Outperform
Sep 17, 2025	HC Wainwright & Co.	Brandon Folkes—	-0.6%	$10 → $10	Maintained	Buy
Aug 19, 2025	Leerink Partners	Roanna Ruiz—	-10.5%	$7 → $9	Maintained	Outperform
Aug 12, 2025	HC Wainwright & Co.	Brandon Folkes—	-0.6%	$10	Assumes	Buy
Aug 8, 2025	Craig-Hallum	Chase Knickerbocker—	+9.3%	$7 → $11	Maintained	Buy
Aug 8, 2025	Oppenheimer	Leland Gershell—	-20.5%	$7 → $8	Maintained	Outperform
Jun 5, 2025	Leerink Partners	Roanna Ruiz—	-30.4%	$6 → $7	Maintained	Outperform
May 9, 2025	Oppenheimer	Leland Gershell—	-30.4%	$6 → $7	Maintained	Outperform
Mar 7, 2025	Oppenheimer	Leland Gershell—	-40.4%	$5 → $6	Maintained	Outperform
Mar 7, 2025	Leerink Partners	Roanna Ruiz—	-40.4%	$5 → $6	Maintained	Outperform
Mar 7, 2025	Craig-Hallum	Chase Knickerbocker—	-35.4%	$5 → $7	Maintained	Buy
Mar 7, 2025	Piper Sandler	David Amsellem—	-60.2%	$3 → $4	Maintained	Neutral
Mar 7, 2025	HC Wainwright & Co.	Oren Livnat—	-20.5%	$7 → $8	Maintained	Buy
Jan 29, 2025	Jefferies	Glen Santangelo—	-40.4%	$4 → $6	Maintained	Buy
Nov 11, 2024	HC Wainwright & Co.	Oren Livnat—	-34.4%	$6 → $7	Maintained	Buy
Nov 11, 2024	Piper Sandler	David Amsellem—	-70.2%	$3 → $3	Downgrade	Overweight→Neutral